Multiple Myeloma MRD guidelines
The updated NCCN Multiple Myeloma Guidelines, Version 1.2027 (September 9, 2026), now provide specific recommendations for when to perform measurable residual disease (MRD) testing, including clonoSEQ.
NCCN-recommended MRD testing timepoints
Timepoint | Recommendation |
At diagnosis | Obtain baseline clonotype identification for future NGS testing (once only). |
After induction therapy | Assess depth of response. |
After autologous stem cell transplant | Approximately day +100 (3 months). |
After CAR T-cell therapy | Approximately 3 months after infusion. |
After treatment for relapse or major regimen change | Reassess MRD response. |
During maintenance therapy | Annually as a general recommendation. |
During surveillance | Generally annually, individualized to clinical circumstances. |


Comments